SY 5933
Alternative Names: SY-5933Latest Information Update: 22 Sep 2023
At a glance
- Originator Shouyao Holdings
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 10 Aug 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (PO) (NCT06006793)